Gene expression signature-based prognostic risk score in patients with glioblastoma

Cancer Science

Volumn 104, Issue 9, 2013, Pages 1205-1210

  Kawaguchi, Atsushi ^a   Yajima, Naoki ^b   Tsuchiya, Naoto ^b   Homma, Jumpei ^b   Sano, Masakazu ^b   Natsumeda, Manabu ^b   Takahashi, Hitoshi ^b   Fujii, Yukihiko ^b   Kakuma, Tatsuyuki ^a   Yamanaka, Ryuya ^c  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NIIGATA UNIVERSITY   (Japan)

^c KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

NIMUSTINE; RNA; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CLINICAL ARTICLE; EXTERNAL BEAM RADIOTHERAPY; FEMALE; GENE; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN GENOME; HUMAN TISSUE; MALE; PREDICTION; PRIORITY JOURNAL; SCORING SYSTEM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; RNA; SURVIVAL ANALYSIS; TRANSCRIPTOME; YOUNG ADULT;

EID: 84883465624     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12214     Document Type: Article

References (25)

1. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002; 359: 1011-8.
2. Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459-66.
3. Kleihues P, Louis DN, Wiestler OD et al. WHO grading of tumours of the central nervous system. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, eds. World Health Organization Classification of Tumours of the Nervous System. Lyon, France: IARC Press, 2007; 10-11.
4. van de Vijver MJ, He YD, van't Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009.
5. Godard S, Getz G, Delorenzi M et al. Classification of human astrocyticgliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res 2003; 63: 6613-25.
6. Nutt CL, Mani DR, Betensky RA et al. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 2003; 63: 1602-7.
7. Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100: 8418-23.
8. Freije WA, Castro-Vargas FE, Fang Z et al. Gene expression profiling of gliomas strongly predicts survival. Cancer Res 2004; 64: 6503-10.
9. Rich JN, Hans C, Jones B et al. Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res 2005; 65: 4051-8.
10. Phillips HS, Kharbanda S, Chen R et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006; 9: 157-73.
11. Yamanaka R, Arao T, Yajima N et al. Identification of expressed genes characterizing long-term survival in malignant glioma patients. Oncogene 2006; 25: 5994-6002.
12. Petalidis LP, Oulas A, Backlund M et al. Improved grading and survival prediction of human astrocytic brain tumors by artificial neural network analysis of gene expression microarray data. Mol Cancer Ther 2008; 7: 1013-24.
13. Verhaak RGW, Hoadley KA, Purdom E et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010; 17: 98-110.
14. Kawaguchi A, Yajima N, Komohara Y et al. Identification and validation of a gene expression signature that predicts outcome in malignant glioma patients. Int J Oncol 2012; 40: 721-30.
15. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-8.
16. Nakasu S, Fukami T, Baba K, Matsuda M. Immunohistochemical study for O6-methylguanine-DNA methyltransferase in the non-neoplastic and neoplastic components of gliomas. J Neurooncol 2004; 70: 333-40.
17. Balss J, Meyer J, Mueller W et al. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 2008; 116: 597-602.
18. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing, 2011. [Cited 10 Dec 2012.] Available from URL: http://www.R-project.org.
19. Gentleman R, Carey V, Bates D et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004; 5: R80.
20. Ishwaran H, Kogalur UB, Gorodeski EZ et al. High-dimensional variable selection for survival data. J Amer Stat Assoc 2010; 105: 205-17.
21. Youden WJ. Index for rating diagnostic tests. Cancer 1950; 3: 32-5.
22. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455: 1061-8.
23. LeBlanc M, Crowley J. Relative risk trees for censored survival data. Biometrics 1992; 48: 411-25.
24. Cordell HJ. Detecting gene-gene interactions that underlie human diseases. Nat Rev Genet 2009; 10: 392-404.
25. Kawaguchi A, Iwadate Y, Komohara Y et al. Gene expression signature-based prognostic risk score in patients with primary central nervous system lymphoma. Clin Cancer Res 2012; 18: 5672-81.